Drug Phase Transformation and Water Redistribution during Continuous Tablet Manufacturing: A Case Study of Carbamazepine Dihydrate

In recent years, continuous tablet manufacturing technology has been used to obtain regulatory approval of several new drug products. While a significant fraction of active pharmaceutical ingredients exists as hydrates (wherein water is incorporated stoichiometrically in the crystal lattice), the im...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 20; no. 7; pp. 3427 - 3437
Main Authors Munjal, Bhushan, DeBoyace, Kevin, Cao, Fengjuan, Krzyzaniak, Joseph F., Arora, Kapildev K., Suryanarayanan, Raj
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 03.07.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In recent years, continuous tablet manufacturing technology has been used to obtain regulatory approval of several new drug products. While a significant fraction of active pharmaceutical ingredients exists as hydrates (wherein water is incorporated stoichiometrically in the crystal lattice), the impact of processing conditions and formulation composition on the dehydration behavior of hydrates during continuous manufacturing has not been investigated. Using powder X-ray diffractometry, we monitored the dehydration kinetics of carbamazepine dihydrate in formulations containing dibasic calcium phosphate, anhydrous (DCPA), mannitol, or microcrystalline cellulose. The combined effect of nitrogen flow and vigorous mixing during the continuous mixing stage of tablet manufacture facilitated API dehydration. Dehydration was rapid and most pronounced in the presence of DCPA. The dehydration product, amorphous anhydrous carbamazepine, sorbed a significant fraction of the water released by dehydration. Thus, the dehydration process resulted in a redistribution of water in the powder blend. The unintended formation of an amorphous dehydrated phase, which tends to be much more reactive than its crystalline counterparts, is of concern and warrants further investigation.
AbstractList In recent years, continuous tablet manufacturing technology has been used to obtain regulatory approval of several new drug products. While a significant fraction of active pharmaceutical ingredients exists as hydrates (wherein water is incorporated stoichiometrically in the crystal lattice), the impact of processing conditions and formulation composition on the dehydration behavior of hydrates during continuous manufacturing has not been investigated. Using powder X-ray diffractometry, we monitored the dehydration kinetics of carbamazepine dihydrate in formulations containing dibasic calcium phosphate, anhydrous (DCPA), mannitol, or microcrystalline cellulose. The combined effect of nitrogen flow and vigorous mixing during the continuous mixing stage of tablet manufacture facilitated API dehydration. Dehydration was rapid and most pronounced in the presence of DCPA. The dehydration product, amorphous anhydrous carbamazepine, sorbed a significant fraction of the water released by dehydration. Thus, the dehydration process resulted in a redistribution of water in the powder blend. The unintended formation of an amorphous dehydrated phase, which tends to be much more reactive than its crystalline counterparts, is of concern and warrants further investigation.
Author Arora, Kapildev K.
Suryanarayanan, Raj
Munjal, Bhushan
DeBoyace, Kevin
Cao, Fengjuan
Krzyzaniak, Joseph F.
AuthorAffiliation Drug Product Design
Pfizer Worldwide Research and Development
Department of Pharmaceutics, College of Pharmacy
AuthorAffiliation_xml – name: Department of Pharmaceutics, College of Pharmacy
– name: Drug Product Design
– name: Pfizer Worldwide Research and Development
Author_xml – sequence: 1
  givenname: Bhushan
  orcidid: 0000-0003-2154-9599
  surname: Munjal
  fullname: Munjal, Bhushan
  organization: Department of Pharmaceutics, College of Pharmacy
– sequence: 2
  givenname: Kevin
  surname: DeBoyace
  fullname: DeBoyace, Kevin
  organization: Drug Product Design
– sequence: 3
  givenname: Fengjuan
  surname: Cao
  fullname: Cao, Fengjuan
  organization: Drug Product Design
– sequence: 4
  givenname: Joseph F.
  surname: Krzyzaniak
  fullname: Krzyzaniak, Joseph F.
  organization: Drug Product Design
– sequence: 5
  givenname: Kapildev K.
  orcidid: 0000-0002-7251-7610
  surname: Arora
  fullname: Arora, Kapildev K.
  email: kapildev.arora@pfizer.com
  organization: Drug Product Design
– sequence: 6
  givenname: Raj
  orcidid: 0000-0002-6322-0575
  surname: Suryanarayanan
  fullname: Suryanarayanan, Raj
  email: surya001@umn.edu
  organization: Department of Pharmaceutics, College of Pharmacy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37232571$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1PG0EMhkcVqHy0f6Eabr0kzMdudrc3FCgggUCQqseVd8ZLBu3OhPk4pEd-OROSIvXWk2359WPZ7xHZs84iISecTTkT_BRUmI5uWC3Bj6AwxalUjLGZ_EQOeVnISS0bsfeR18UBOQrhmTFRlEJ-JgeyElKUFT8kr-c-PdH7JQSkCw829C4zo3GWgtX0N0T09AG1CdGbLr03dPLGPtG5s9HY5FKgC-gGjPQWbOpBxff-D3pG5xvsY0x6TV2fK9_BCH9wZSzSc7Nca5_5X8h-D0PAr7t4TH79vFjMryY3d5fX87ObCUhWxUnNdIdyVoJiqqlZNetF1Tei4rVo6qJgwHvOUZYdV1orzHXXAZONlEXJxUzLY_J9y11595IwxHY0QeEwgMV8RCtqwVh-WcWztNlKlXcheOzblTcj-HXLWbuxoM0WtP9Y0O4syLPfdmtSN6L-mPz78ywot4IN49klb_PV_wF-Ayrnnh8
Cites_doi 10.3390/PHARMACEUTICS13081311
10.1021/acs.oprd.1c00197
10.1002/JPS.21443
10.1002/9781119600800.CH72
10.1016/J.XPHS.2022.08.029
10.1016/J.EJPS.2021.106086
10.1021/JS960117E
10.1248/CPB.44.1065
10.3109/03639048809151997
10.1002/JPS.2600670609
10.3109/10837459809028643
10.1016/j.trac.2021.116181
10.1107/S0567740881007383
10.1016/J.IJPHARM.2021.121065
10.1016/S0731-7085(00)00262-4
10.1016/J.XPHS.2021.01.035
10.1081/PDT-100100540
10.1016/S0169-409X(99)00018-6
10.1016/B978-0-12-813479-5.00003-3
10.1002/JPS.20532
10.1023/A:1015970218980
10.1021/acs.molpharmaceut.1c00217
10.1208/PT040468
10.1021/acs.molpharmaceut.8b00340
10.1002/3527607889.CH8
10.1016/J.POWTEC.2012.04.059
10.1016/j.xphs.2018.07.018
10.1016/J.ADDR.2021.113840
10.1016/J.IJPHARM.2018.12.058
10.1002/CRAT.2170211118
10.1002/JPS.2600640805
10.1038/nrd1550
10.1007/s12247-018-9313-5
10.1016/J.IJPHARM.2018.09.032
10.1016/J.XPHS.2020.12.040
10.1002/(sici)1520-6017(200004)89:4<457::aid-jps3>3.0.co;2-g
10.1002/jps.20191
10.1007/s11095-012-0698-4
ContentType Journal Article
Copyright 2023 American Chemical Society
Copyright_xml – notice: 2023 American Chemical Society
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1021/acs.molpharmaceut.3c00063
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1543-8392
EndPage 3437
ExternalDocumentID 10_1021_acs_molpharmaceut_3c00063
37232571
e46649854
Genre Journal Article
GroupedDBID ---
-~X
123
4.4
53G
55A
5VS
7~N
AABXI
ABFRP
ABMVS
ABQRX
ABUCX
ACGFS
ACS
ADHLV
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
DU5
EBS
ED~
F5P
GGK
GNL
H~9
IH9
JG~
P2P
RNS
ROL
UI2
VF5
VG9
W1F
ABJNI
BAANH
CUPRZ
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-a307t-80dbe365ac0c98076f27f92718298440a1f11e35b1cddce0a1bba0393345126d3
IEDL.DBID ACS
ISSN 1543-8384
IngestDate Fri Aug 16 04:36:07 EDT 2024
Fri Aug 23 01:51:37 EDT 2024
Wed Oct 16 00:38:14 EDT 2024
Thu Jul 06 08:30:33 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords moisture redistribution
dibasic calcium phosphate
PCMM
continous mixing
dehydration
continuous manufacturing
hydrate
carbamazepine
drug phase transformation
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a307t-80dbe365ac0c98076f27f92718298440a1f11e35b1cddce0a1bba0393345126d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2154-9599
0000-0002-7251-7610
0000-0002-6322-0575
PMID 37232571
PQID 2820015471
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_2820015471
crossref_primary_10_1021_acs_molpharmaceut_3c00063
pubmed_primary_37232571
acs_journals_10_1021_acs_molpharmaceut_3c00063
PublicationCentury 2000
PublicationDate 2023-07-03
PublicationDateYYYYMMDD 2023-07-03
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-03
  day: 03
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2023
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref6/cit6
ref3/cit3
ref27/cit27
ref18/cit18
European Medicines Agency (ref8/cit8) 2021
Krogmeier S. (ref4/cit4) 2022
ref11/cit11
ref25/cit25
ref16/cit16
ref29/cit29
European Medicines Agency (ref7/cit7) 2020
ref32/cit32
ref23/cit23
ref39/cit39
ref14/cit14
ref5/cit5
ref31/cit31
ref2/cit2
ref34/cit34
ref37/cit37
ref28/cit28
ref40/cit40
ref20/cit20
ref17/cit17
ref10/cit10
ref26/cit26
ref35/cit35
ref19/cit19
ref21/cit21
ref12/cit12
ref15/cit15
ref42/cit42
ref41/cit41
ref22/cit22
Sheskey P. J. (ref36/cit36) 2020
ref13/cit13
ref33/cit33
ref30/cit30
ref1/cit1
ref24/cit24
ref38/cit38
References_xml – ident: ref5/cit5
  doi: 10.3390/PHARMACEUTICS13081311
– volume-title: Committee for Medicinal Products for Human Use (CHMP)
  year: 2020
  ident: ref7/cit7
  contributor:
    fullname: European Medicines Agency
– ident: ref11/cit11
  doi: 10.1021/acs.oprd.1c00197
– ident: ref35/cit35
  doi: 10.1002/JPS.21443
– ident: ref2/cit2
  doi: 10.1002/9781119600800.CH72
– ident: ref34/cit34
  doi: 10.1016/J.XPHS.2022.08.029
– ident: ref18/cit18
  doi: 10.1016/J.EJPS.2021.106086
– ident: ref26/cit26
  doi: 10.1021/JS960117E
– ident: ref38/cit38
  doi: 10.1248/CPB.44.1065
– ident: ref13/cit13
  doi: 10.3109/03639048809151997
– ident: ref42/cit42
  doi: 10.1002/JPS.2600670609
– ident: ref21/cit21
  doi: 10.3109/10837459809028643
– ident: ref24/cit24
  doi: 10.1016/j.trac.2021.116181
– ident: ref29/cit29
  doi: 10.1107/S0567740881007383
– ident: ref10/cit10
  doi: 10.1016/J.IJPHARM.2021.121065
– ident: ref37/cit37
  doi: 10.1016/S0731-7085(00)00262-4
– ident: ref6/cit6
– ident: ref9/cit9
  doi: 10.1016/J.XPHS.2021.01.035
– ident: ref23/cit23
  doi: 10.1081/PDT-100100540
– ident: ref41/cit41
  doi: 10.1016/S0169-409X(99)00018-6
– start-page: 383
  volume-title: How to Design and Implement Powder-To-tablet Continuous Manufacturing Systems
  year: 2022
  ident: ref4/cit4
  doi: 10.1016/B978-0-12-813479-5.00003-3
  contributor:
    fullname: Krogmeier S.
– ident: ref25/cit25
  doi: 10.1002/JPS.20532
– ident: ref22/cit22
  doi: 10.1023/A:1015970218980
– volume-title: Handbook of Pharmaceutical Excipients
  year: 2020
  ident: ref36/cit36
  contributor:
    fullname: Sheskey P. J.
– ident: ref17/cit17
  doi: 10.1021/acs.molpharmaceut.1c00217
– ident: ref20/cit20
  doi: 10.1208/PT040468
– ident: ref31/cit31
  doi: 10.1021/acs.molpharmaceut.8b00340
– volume-title: Committee for Medicinal Products for Human Use
  year: 2021
  ident: ref8/cit8
  contributor:
    fullname: European Medicines Agency
– ident: ref14/cit14
  doi: 10.1002/3527607889.CH8
– ident: ref27/cit27
  doi: 10.1016/J.POWTEC.2012.04.059
– ident: ref39/cit39
  doi: 10.1016/j.xphs.2018.07.018
– ident: ref1/cit1
  doi: 10.1016/J.ADDR.2021.113840
– ident: ref15/cit15
  doi: 10.1016/J.IJPHARM.2018.12.058
– ident: ref30/cit30
  doi: 10.1002/CRAT.2170211118
– ident: ref12/cit12
  doi: 10.1002/JPS.2600640805
– ident: ref40/cit40
  doi: 10.1038/nrd1550
– ident: ref3/cit3
  doi: 10.1007/s12247-018-9313-5
– ident: ref28/cit28
  doi: 10.1016/J.IJPHARM.2018.09.032
– ident: ref32/cit32
  doi: 10.1016/J.XPHS.2020.12.040
– ident: ref33/cit33
  doi: 10.1002/(sici)1520-6017(200004)89:4<457::aid-jps3>3.0.co;2-g
– ident: ref16/cit16
  doi: 10.1002/jps.20191
– ident: ref19/cit19
  doi: 10.1007/s11095-012-0698-4
SSID ssj0024523
Score 2.435155
Snippet In recent years, continuous tablet manufacturing technology has been used to obtain regulatory approval of several new drug products. While a significant...
SourceID proquest
crossref
pubmed
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 3427
Title Drug Phase Transformation and Water Redistribution during Continuous Tablet Manufacturing: A Case Study of Carbamazepine Dihydrate
URI http://dx.doi.org/10.1021/acs.molpharmaceut.3c00063
https://www.ncbi.nlm.nih.gov/pubmed/37232571
https://search.proquest.com/docview/2820015471
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3LTtwwFLVaKlXd8OiLoYCMVLEi0_iR2OluNIBQJSrUBpVdZDt2iyoSNEkWw7Jf3msnw0CrirKMk1iJc-1zYvuci9B7DRAHw5yLeOpkxK11kcxSGXmzqkQ4J02Y0D_9nJ6c808XycVSx_3nCj4lH5Rpxle1F54OU7xjZgKyPkXPqIgzn69hMv26NNhLQk43oAYskkzy52jvwao8NJnmPjT9g28G3DleQ_lCvdNvN_k57lo9Njd_mzk-5pXW0erAQ_GkD5wN9MRWL9H-WX_t_ADnS11Wc4D38dnS4nr-Cv06nHXffVljcX6H-tYVVlWJvwGBneEvXvJ7m1AL94JI7O2wLquu7hqce9lWi09V1Xl9RTj_EU_w1FfrNzjOce3gaKbVlbqx10CI8eHlj3np7S1eo_Pjo3x6Eg3ZHCIF40gLUFhqy9JEmdhkMhapo8JlFLCRZpLzWBFHiGWJJqYsjYVjrZVXDjMOpCQt2Ru0UtWV3URY0MRRy4UupeVWxVLBuOMyolLAWq7dCEEwNsXQG5siLLRTUvjCe-1eDO0-QnTx5Yvr3uXjf27aW8RIAX3SL7SoykLzFfAbG7ipICP0tg-e22qZAA6bCLL12Gd8h174VPdhqzDbRivtrLM7QIhavRs6wG-eiAuM
link.rule.ids 315,783,787,2774,27090,27938,27939,57072,57122
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkYAL78fydCXUU7PEsRM73FZbqgW6VQWpqNRDZCc2VKhJtUkO2yO_nLGT7lIkxOMYJxk5o7Hniz3fZ4BXGlMcTnM24ImVATfGBjJNZODEqmJhrSz8gv58P5kd8vdH8dFQVem4MNiJBi01fhN_rS5AX7u209rxT4eV3jErfIK9CtdiEQp3esFk-mmtsxf7o90QIbBAMsmvw-YfTbkMVTSXM9RvYKdPP7u34XjVcV918m3ctXpcnP-i6fh_X3YHbg2olEz6MLoLV0x1D7YO-meX2yRbs7SabbJFDtaC18v78H1n0X1xbY0h2U9AuK6IqkryGeHsgnx0BODV8Vqkp0cSJ451UnV115DMkbhaMldV59gW_v4bMiFTZ9aVOy5JbfFqodWpOjdnCI_JzsnXZenELh7A4e7bbDoLhrMdAoWzSouJsdSGJbEqwiKVoUhsJGwaYaaMUsl5qKil1LBY06IsC4PXWivHI2YcIUpSsoewUdWVeQxERLGNDBe6lIYbFUqFs5BNqUow83JtR-Dcng9js8n9tntEc9d4ye_54PcRRBcBkJ_1mh9_89LmRajkOELdtouqDLovx59aj1QFHcGjPoZWZplARBsL-uRf-_gSbsyy-V6-927_w1O4GSH08kXE7BlstIvOPEeo1OoXfkz8AJgzE_U
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBWXUt5LC7gS6qnZrh0ncbitdlmVR6sVbEVvlp3YUFVNVpvksD32lzPjpLsUCfE4xkksZzTj74vtb4aQNwYgDqY5F4jYyUBY6wKZxjLAZFVR4pzM_IL-8Ul8dCo-nEVn3YIbamFgEBX0VPlNfIzqee66DAPsENsvS9Sgdqu9_TDzIHuX3IsSxrGCwXD0ZZ1rL_Ll3YAlhIEMpdgke3_sClEqq26j1G-op4egyQOiVoP3J08u-k1t-tnVL3kd___rtslWx07psHWnh-SOLR6R_Wn77PKAztZqreqA7tPpOvH18jG5Hi-ab9hWWTr7iRCXBdVFTr8CrV3QzygEXpXZoq1MkmKSrPOiKZuKzlDMVdNjXTSouvD339IhHWG3eOxxSUsHVwujL_WVnQNNpuPz78sck148IaeTd7PRUdDVeAg0zC41AGRubBhHOhtkqRwkseOJSzkgJk-lEAPNHGM2jAzL8jyzcG2MRj1xKICqxHn4lGwUZWGfE5rwyHErEpNLK6weSA2zkUuZjgGBhXE9gqZXXYxWym-_c6aw8ZbdVWf3HuE3TqDmbe6Pv3lp78ZdFEQqbr_owoL5FPzcesaasB551vrRqtswAWYLLvziX8f4mmxOxxP16f3Jxx1ynwMD82eJw12yUS8a-xIYU21e-bD4ATAuFm8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Drug+Phase+Transformation+and+Water+Redistribution+during+Continuous+Tablet+Manufacturing%3A+A+Case+Study+of+Carbamazepine+Dihydrate&rft.jtitle=Molecular+pharmaceutics&rft.au=Munjal%2C+Bhushan&rft.au=DeBoyace%2C+Kevin&rft.au=Cao%2C+Fengjuan&rft.au=Krzyzaniak%2C+Joseph+F.&rft.date=2023-07-03&rft.pub=American+Chemical+Society&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=20&rft.issue=7&rft.spage=3427&rft.epage=3437&rft_id=info:doi/10.1021%2Facs.molpharmaceut.3c00063&rft.externalDocID=e46649854
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon